Last reviewed · How we verify
NCT02906124
Study to Evaluate the Safety of Repatha® in Pregnancy
trial in Hypercholesterolaemia in 4 participants. Terminated before completion.
6 November 2020
Quick facts
| Lead sponsor | Amgen |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 4 |
| Start date | 12 January 2017 |
| Primary completion | 6 November 2020 |
| Estimated completion | 6 November 2020 |
| Sites | 48 locations across Denmark, Italy, Netherlands, Slovakia, Greece, Belgium, Austria, Sweden |
Conditions studied
- Hypercholesterolaemia — all drugs for Hypercholesterolaemia →
- Pregnancy — all drugs for Pregnancy →
Sponsor
Amgen — full company profile →
Who can join
Eligibility, female only, with Hypercholesterolaemia or Pregnancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate pregnancy and infant outcomes among females diagnosed with familial hypercholesterolaemia (FH), exposed to Repatha® during pregnancy. This includes follow-up of their infants to the age of 12 months
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Safety and Tolerability of PCSK9 Inhibitors: Current Insights.
Kosmas CE, Skavdis A, Sourlas A, Papakonstantinou EJ, et al · · 2020 · cited 34× · PMID 33335431 · DOI 10.2147/cpaa.s288831
Verify or expand the search:
- PubMed search for NCT02906124
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypercholesterolaemia
Currently open trials in the same condition.
- NCT06974266 — An Efficacy and Safety Study of Akkermansia Muciniphila AKM Lab-01 in Hypercholesterolaemia · NA · recruiting
- NCT06501443 — LATAM LOWERS LDL-C · Phase 4 · recruiting
- NCT07375225 — Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy · recruiting
- NCT06275724 — Specified Drug-use Survey of Leqvio for s.c. Injection. · active not recruiting
- NCT06008756 — Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes · Phase 3 · active not recruiting
Other Amgen trials
Trials by the same sponsor.
- NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
- NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
- NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
- NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
- NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02906124 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Amgen
- Last refreshed: 22 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02906124.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing